It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
On April 30, AstraZeneca and the University of Oxford announced a “landmark agreement” for the development of a COVID-19 vaccine. The agreement involves AstraZeneca overseeing aspects of the development as well as manufacturing and distribution while the Oxford side, via the Jenner Institute and Oxford Vaccine Group, researched and developed the vaccine. Less than a month after this agreement was reached, the Oxford-AstraZeneca partnership was awarded a contract from the US government as part of Operation Warp Speed, the public-private COVID-19 vaccination effort dominated by the US military and US intelligence.
For much of 2020, the Oxford-AstraZeneca vaccine was treated as an early frontrunner, though its lead would later be marred by scandals related to its clinical trials, including the death of participants, sudden trial pauses, the use of a problematic “placebo” with its own host of side effects, and the “unintentional” misdosing of some participants that skewed its self-reported efficacy rate.
While the controversies surrounding the vaccine’s trials did ultimately undermine its previous frontrunner status, the Oxford-AstraZeneca vaccine remains heavily promoted as the vaccine of choice for the developing world, as it is cheaper and has much less complicated storage requirements than its main competitors, Pfizer and Moderna.
mainstream media has had little, if anything, to say about the role of the vaccine developers’ private company—Vaccitech—in the Oxford-AstraZeneca partnership, a company whose main investors include former top Deutsche Bank executives, Silicon Valley behemoth Google, and the UK government. All of them stand to profit from the vaccine alongside the vaccine’s two developers, Adrian Hill and Sarah Gilbert, who retain an estimated 10 percent stake in the company. Another overlooked point is the plan to dramatically alter the current sales model for the vaccine following the initial wave of its administration, which would see profits soar, especially if the now-obvious push to make COVID-19 vaccination an annual affair for the foreseeable future is made reality.
Arguably most troubling of all is the direct link of the vaccine’s lead developers to the Wellcome Trust and, in the case of Adrian Hill, the Galton Institute, two groups with longstanding ties to the UK eugenics movement. The latter organization, named for the “father of eugenics” Francis Galton, is the renamed UK Eugenics Society, a group notorious for over a century for its promotion of racist pseudoscience and efforts to “improve racial stock” by reducing the population of those deemed inferior.
originally posted by: slatesteam
You would....
originally posted by: smurfy
a reply to: dug88
Not too sure about this with Corbett in the frame, too whacko an individual for comfort.
I will look for other sources.
GL!
originally posted by: dollukka
Got astra zeneca yesterday... with very mild side effects ( milder than influenza vaccine symptoms ). Today nothing unordinary. What comes to eugenics i am pretty sure every lab company is involved. Covid itself has been racial, hitting hardest on people who have african, asian and spanish roots.
originally posted by: TheAMEDDDoc
That sounds nice, I wouldn’t be comfortable with this vaccine, it’s efficacy is too low and these are the types of vaccines that cause ADE in other SARS like coronavirus studies.
The only ones I would get are Pfizer and Moderna, in that order because Moderna dose 2 sucks, and no one I know has had an issue with Pfizer. This thing is only 60-70% effective in a controlled environment, the delivery system could make bad antibodies and in the real world I don’t see it working well, probably 20-30% lower.